active
ACTIVE SINCE: 2018, re-launched in 2021

AMR register (previously known as AMR Open Surveillance Data)

AMR Register provides information from the biopharmaceutical industry's antimicrobial resistance (AMR) surveillance programs to inform national and international policy on AMR developments.
SGDS CONTRIBUTING TO:
SHOW SUB-TARGETS + HIDE SUB-TARGETS -
MEMBER COMPANIES:
Private Foundation or Development Organization 1
Global NGOs 2
Pharma (non-IFPMA member) 2
Objectives
  • Identify resistant pathogen outbreaks and recognize new resistance. mechanisms as they emerge.
  • Analyze data over time to detect trends in multi-drug resistance.
  • Provide trustworthy global and regional in vitro susceptibility data.
  • Inform national and international policy and antibiotic stewardship.
  • Allow for the prediction of future resistance trends.

Antimicrobial resistance (AMR) is a growing threat to global health. Currently, at least 700,000 people die each year from drug-resistant infections, a figure that the United Nations predicts will rise to 10 million by 2050.

The AMR crisis requires big data to fully comprehend its trends and patterns of resistance. The biopharmaceutical industry routinely collects surveillance data to monitor clinical susceptibility to marketed products or meet regulatory approval requirements for new products.

Over 100 biopharmaceutical companies and trade associations signed The Davos Declaration on Antibiotic Resistance in 2016. They later released the Industry Roadmap for Progress on Combating Antimicrobial Resistance ahead of the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance, pledging to share surveillance data and make it available to public health bodies and healthcare professionals.

AMR Register fulfills this pledge by collecting published data from industry-sponsored human antimicrobial surveillance programs to generate a  global platform for sharing AMR surveillance data.  The project fosters international collaboration and develops a shared and sustainable framework for using datasets with the active participation of leading biopharmaceutical organizations. This project allows biopharmaceutical organizations to securely share their data with researchers, national governments, and multi-lateral organizations such as the United Nations, CDC, and the World Health Organization (WHO).

Quote
"GSK has been sharing its clinical study data since 2004. We are excited to share the data from our antibiotic surveillance studies that were running during the last 5 years. We hope that the scientific community will benefit from the data."
Dr Didem Torumkuney
Scientific Director, Infectious Diseases, GSK
"Surveillance is crucial for clinicians and public health officials in assessing the nature and scope of emerging resistance locally and nationally. ATLAS is capable of providing such a broad scope of reliable, readily available information."
Dr Matteo Bassetti
Chief of the Infectious Diseases Clinic at University of Udine in Italy
Results and milestones
  • On 21 June 2022, leading biopharmaceutical companies joined Vivli for the AMR Register launch.
  • Between 2004 and 2020, the AMR Register has received data sets from seven companies, totaling 925,000 bacterial isolates collected in more than 80 countries.
  • The pilot website launched during the ESCMID/ASM Congress in 2018: amr.theodi.org
Geographic Reach
  • Global Commitment
Disease Area
  • Infectious and Parasitic Disease
See Disease Areas
Partner organizations
Private Foundation or Development Organization
Wellcome
Trust

Both Wellcome Trust and Open Data Institute have experience from running a a number of open data programmes in other sectors, which have shown that benefits can best be realised through structured, well-defined, independently managed efforts that promote not only the publication of open data to agreed standards but also open innovation to create useful products and services, and their use by decision-makers

Global NGOs
Open Data Institute
(ODI)

Both Wellcome Trust and Open Data Institute have experience from running a a number of open data programmes in other sectors, which have shown that benefits can best be realised through structured, well-defined, independently managed efforts that promote not only the publication of open data to agreed standards but also open innovation to create useful products and services, and their use by decision-makers

Vivli

Pharma (non-IFPMA member)

Paratek

Vanatorx

Additional resources

FURTHER READING